6ML0 Stock Chart & Stats
€3.66
-€0.02(-0.61%)
At close: 4:00 PM EDT
€3.66
-€0.02(-0.61%)
Day’s Range― - ―
52-Week Range€2.92 - €4.30
Previous CloseN/A
Volume0.00
Average Volume (3M)219.00
Market Cap
€161.44M
Enterprise Value€67.80
Total Cash (Recent Filing)€67.69M
Total Debt (Recent Filing)€3.03M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Mar 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding40,374,640
10 Day Avg. Volume85
30 Day Avg. Volume219
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.60
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.73Price Target Upside193.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway Supports Continued DevelopmentThe cash balance and projected runway provide funding visibility for advancing clinical programs without immediate financing pressure, giving management time to generate development data and pursue partnerships.
Radio-DARPin Pipeline Is Advancing ClinicallyProgressing MP0712 into additional dosing supports the platform’s clinical feasibility and may establish a lead asset in targeted alpha radiotherapy, a differentiated area with potential for broader pipeline validation.
Diversified Oncology Pipeline Reduces Single-asset RelianceMultiple programs across radiopharmaceuticals and immune-cell engagers create several opportunities for clinical value creation, reducing dependence on one candidate and expanding potential partnering or commercialization paths.
Bears Say
No Current Revenue And Persistent LossesThe absence of recurring revenue leaves the company dependent on intermittent licensing or milestone income, while sustained losses limit financial self-sufficiency and increase reliance on future asset or partnership success.
Ongoing Cash Burn Pressures Financial ResourcesContinued operating outflows consume the cash base required to fund research and trials. Even with a long runway, persistent burn may eventually require financing, partnering proceeds, or spending reductions.
Clinical-stage Pipeline Carries Substantial Execution RiskMost value-creating programs remain early in clinical development, so regulatory, safety, efficacy and enrollment outcomes are unresolved. Delayed or negative results could materially weaken future partnering and funding prospects.
Molecular Partners News
6ML0 FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was €2.92 and its highest was €4.30 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is €161.44M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 18, 2027 which is in 200 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 25, 2026. The company reported -€0.374 earnings per share for the quarter, missing the consensus estimate of -€0.371 by -€0.003.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -€0.374 in its last earnings report, missing expectations of -€0.371. Following the earnings report the stock price went down -4.348%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in DE:6ML0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
6ML0 Stock 12 Month Forecast
Average Price Target
€10.73
▲(193.16% Upside)